Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

BACKGROUND: T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC). The cause of resistance in the remaining half of the cases is a minor mutation or unknown. Here, we conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Tadashi, Okano, Tomohito, Naito, Masahiro, Iwanaka, Soichi, Ohiwa, Ayaka, Sakakura, Yasumasa, Yasuma, Taro, Fujimoto, Hajime, D'Alessandro‐Gabazza, Corina N., Oomoto, Yasuhiro, Kobayashi, Tetsu, Gabazza, Esteban C., Ibata, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017249/
https://www.ncbi.nlm.nih.gov/pubmed/33586356
http://dx.doi.org/10.1111/1759-7714.13870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017249/
https://www.ncbi.nlm.nih.gov/pubmed/33586356
http://dx.doi.org/10.1111/1759-7714.13870

Ejemplares similares